News & Events

Redbiotec is collaborating with ETH Zurich in testing advantages of co-expression using IkappaB kinase (IKK) as an example. Activity of several IKK complex variations will be tested.

Biopharmaceuticals – i.e. protein based drugs – are one of the fastet growing type of drugs and expertise on the industrial production will be increasingly sought off. Thus Redbiotec started a collaboration with the department of Prof. Dr. Thierry Voléry from the University of St. Gallen in the form of a master thesis.In the next 6 month to come current industrial production processes will be systematically analysed upon optimization potential through the leading baculovirus technology of redbiotec.

Redbiotec has successfully expressed difficult to produce proteins – kinases – for the german biotech company Crelux. The proteins are being used as drug targets for the discovery of pharmaceuticals.Though time was short, Redbiotec mastered the challenge of significantly increasing the yield. „Redbiotec has been the perfect partner for our challenging projects.Therefore we will tighten our collaboration in the future.” Dr. Ismail Moarefi, Chief Scientific OfficerCrelux, Munich

Redbiotec is strengthening its team by hiring highly qualified people in research and development.

Rebiotec sealed its first work contract deals with an industrial customer and is actively pursuing negotiations with other potential customers in the pharma/ biotech sectors.